Bjoern Bauer

Bjoern Bauer, PhD is a Professor in the Department of Pharmaceutical Sciences at the University of Kentucky, affiliated with the Sanders-Brown Center on Aging. His research focuses on blood-brain barrier (BBB) biology, Alzheimer’s disease mechanisms, and drug delivery strategies for neurological disorders. Bauer’s work explores how BBB dysfunction contributes to neurodegenerative diseases and cancer, with particular attention to efflux transporters like P-glycoprotein (ABCB1) and their roles in drug resistance and amyloid beta pathology.

Key research areas include: 1) BBB leakage and its role in Alzheimer’s disease progression, 2) development of therapeutic strategies to modulate BBB transporters, 3) preclinical models of glioblastoma and neurodegeneration, and 4) biomarker discovery for early disease detection. His lab utilizes advanced in vitro BBB models, transgenic mouse models (e.g., 5xFAD), and imaging techniques to study these processes.

Bauer’s contributions span over 40 peer-reviewed publications since 2001, with recent work emphasizing oxidative stress mechanisms, tumor drug resistance, and translational approaches to BBB targeting. Current efforts include investigating S100β as a plasma biomarker and exploring proteasome inhibition as a therapeutic avenue for restoring BBB integrity. He leads the Bauer-Hartz Lab, collaborating extensively with neurologists, oncologists, and pharmacologists to advance CNS drug delivery technologies.

He holds a PhD in Pharmacology and has been a faculty member at the University of Kentucky since joining Sanders-Brown in [year not explicitly stated]. His research is supported by grants focusing on BBB biology, Alzheimer’s disease, and cancer pharmacology.